What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? DOI
Andrea Dalbeni,

Filippo Cattazzo,

L.A. Natola

et al.

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: March 5, 2025

Hepatocellular carcinoma (HCC) remains a major global health concern, as it is the most common primary liver cancer and fourth leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs) have significantly shifted treatment paradigm, offering promising survival outcomes. However, controlled conditions randomized clinical trials (RCTs) often fail to reflect real-world complexities, emphasizing necessity for strong evidence (RWE). RWE, in cases derived from observational studies, provides critical insights into effectiveness, safety, tolerability systemic therapies across diverse populations settings. The authors searched MEDLINE, Ovid Embase, Scopus full-text published articles any language inception 30 June 2024.This review evaluates RWE on advanced HCC, including tyrosine kinase (TKIs) like sorafenib lenvatinib, ICIs such nivolumab pembrolizumab, combination atezolizumab/bevacizumab durvalumab/tremelimumab. Studies reveal discrepancies efficacy adverse event profiles between RCTs routine practice, underscoring need individualized strategies. highlights influence disease etiology, function, tumor burden outcomes, guiding therapy selection.

Language: Английский

Tertiary lymphoid structure dynamics at the centre of immunotherapy response in hepatocellular carcinoma DOI
David J. Pinato

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Highlighting recent achievements to advance more effective cancer immunotherapy DOI Creative Commons
Beatrice Belmonte, Sheila Spada, Paola Allavena

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: Feb. 18, 2025

Abstract From 17 to 19th October 2024, the XXI Italian Network for Bio-Immunotherapy of Tumors Meeting (NIBIT) took place in Palermo, marvelous historical location Teatro Politeama, under auspices Association Medical Oncology (AIOM), Cancer Research (AIRC), Fondazione Pezcoller, Alliance against (ACC), Lymphoma Foundation (FIL), Grazia Focacci and Melagioco Foundation. The conference covered a spectrum topics ranging from target discovery therapeutic advances immuno-oncology, bringing world-renowned experts present groundbreaking innovations basic, translational, clinical cancer research. Six sessions focused on cellular therapies, digital pathology, vaccines, tertiary lymphoid structures, microenvironment order get deep insights how personalize diagnosis therapies setting. Young investigators had opportunity meet greet their mentors, promoting synergy academic industrial sectors within national international panorama, discussing application artificial intelligence multi-specific antibodies, drug conjugates, antibody fusion proteins that are advancing efficacy precision medicine minimizing off-target effects.

Language: Английский

Citations

0
What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? DOI
Andrea Dalbeni,

Filippo Cattazzo,

L.A. Natola

et al.

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: March 5, 2025

Hepatocellular carcinoma (HCC) remains a major global health concern, as it is the most common primary liver cancer and fourth leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs) have significantly shifted treatment paradigm, offering promising survival outcomes. However, controlled conditions randomized clinical trials (RCTs) often fail to reflect real-world complexities, emphasizing necessity for strong evidence (RWE). RWE, in cases derived from observational studies, provides critical insights into effectiveness, safety, tolerability systemic therapies across diverse populations settings. The authors searched MEDLINE, Ovid Embase, Scopus full-text published articles any language inception 30 June 2024.This review evaluates RWE on advanced HCC, including tyrosine kinase (TKIs) like sorafenib lenvatinib, ICIs such nivolumab pembrolizumab, combination atezolizumab/bevacizumab durvalumab/tremelimumab. Studies reveal discrepancies efficacy adverse event profiles between RCTs routine practice, underscoring need individualized strategies. highlights influence disease etiology, function, tumor burden outcomes, guiding therapy selection.

Language: Английский

Citations

0